866-997-4948(US-Canada Toll Free)

Published on : Jun 13, 2016

ALBANY, New York, June 13, 2016 – ResearchMoz.us has announced the addition of “Global Dermatology Market to 2022 - Innovative Pipeline and Increasing Uptake of Biologics to Diversify Treatment Options and Drive Strong Growth,” a new market research report to its offering. 

This report provides a thorough analysis of the market and helps in understanding the commercial and clinical landscape of the market. The study also incorporates an evaluation on the key dynamics impacting the development of the market such as drivers, opportunities, trends, and inhibitors. The products poised to fuel the growth of the market in the forecast horizon, 2015 to 2022, have also been presented through this study. The study also helps in understanding the composition of the market and highlights the top commercial assets as well as players.

The global dermatology market stood at $20.0 bn in 2015 and is predicted to reach $33.7 bn by 2022, by expanding at a 7.73% CAGR between 2015 and 2022. This report includes a number of dermatological conditions with particular emphasis on the three chief diseases, namely, acne vulgaris, psoriasis, and atopic dermatitis owing to the fact that these conditions are highly prevalent globally and also have the largest therapeutics pipeline. 

The report commences by presenting an overview of the dermatology market. As per the report, dermatological conditions are amongst the most prevalent kinds of disorders globally. In the U.S alone, one-third of the population is suffering from at least a single kind of active skin condition. In the past decade, the dermatology market was considered mature. However, the commercial as well as clinical success of biologics for the treatment of psoriasis and the increasing understanding of a number of dermatological conditions are the key factors responsible for the rising interest in dermatology among numerous pharmaceutical companies globally. 

Click here to get more info with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=725316

Moving further in the report, the factors driving the growth of the market for dermatology have been presented. The increasing adoption of recently approved premium biologics and expected introduction of favorable late-stage products are amongst the major factors stimulating the growth of the market for dermatology. 

In the next section of the report, the treatment options for skin diseases such as acne vulgaris, psoriasis, and atopic dermatitis have been presented. These include topical corticosteroids, calcineurin inhibitors, retinoids, systemic immunosuppressive agents, biologics, antihistamines, hormonal therapy, and moisturizers. 

In the following section of the report, the major marketed products have been presented. These include Humira (adalimumab), Remicade (infliximab), Enbrel (etanercept), Stelara (ustekinumab), Neoral (cyclosporine), Protopic (tacrolimus), Elidel (pimecrolimus), and Elocon. The section on pipeline landscape assessment comes next in the report; it comprises molecule types and molecule targets in the pipeline and clinical trials.

3Gen Inc., Genesis Biosystems, Inc., Alma Lasers, Ltd., Cutera, Inc., and Carl Zeiss, Bruker Corporation are the key players operating in the global dermatology market, as per this study.

To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on sales@researchmoz.us